Tumor necrosis factor not detectable in patients with clinical cancer cachexia

Journal of the National Cancer Institute

Volumn 80, Issue 8, 1988, Pages 595-598

  Socher, Susan H ^a   Martinez, Douglas ^a   Craig, John B ^b   Kuhn, John G ^b   Oliff, Allen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ADULT; AGED; CACHEXIA; CANCER; CLINICAL ARTICLE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BODY WEIGHT; CACHEXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN; MIDDLE AGE; NEOPLASMS; TUMOR NECROSIS FACTOR;

EID: 0023903345     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/80.8.595     Document Type: Article

References (31)

1. CARSWELL EA, OLD LJ, KASSEL RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-3670.
2. MATTHEWS N. Tumor-necrosis factor from the rabbit II. Production by monocytes. Br J Cancer 1978;38:310-315.
3. TRACEY KJ, BEUTLER B, LOWRY SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234: 470-474.
4. KAWAKAMI M, CERAMI A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981;154:631-639.
5. DAYER J-M, BEUTLER B, CERAMI A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-2168.
6. VILCEK J, PALOMBELLA VJ, HENRIKSENDESTAFANO D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632-634.
7. BERTOUNI DR, NEDWIN GE, BRINGMAN TS, et al.' Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
8. DINARELLO CA, CANNON; JG, WOLFF SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin I. J Exp Med 1986;163:1433- 1450.
9. ROUZER CA, CERAMI A. Hypertriglyceridemia associated with Trypanosoma brucd infection in rabbits; role of defective triglyceride removal. Mol Biochem Parasitol 1980;2:31-38.
10. BEUTLER B, GREENWALT D, HULMES JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-554.
11. BEUTLER B, CERAMI A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-588.
12. SEMB H, PETERSON J, TAVERNIER J, et al. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987;262:8390-8394.
13. VLASSARA H, SPIEGEL RJ, DOVAL DS, et al. Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metab Res 1986;18:698-703.
14. CERAMI A, IDEDA Y, LE TRANG N, et al. Weight loss associated with an endotoxininduced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 1985;11:173-177.
15. PATTON JS, PETERS PM, MCCABE J, et al. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents. J Clin Invest 1987;80:1587-1596.
16. OLIFF A, DEFEOJONES D, BOYER M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555- 563.
17. BALKWILL F, BURKE F, TALBOT D, et al. Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 1987;2:1229- 1232.
18. TEPPO AM, MAURY CPJ. Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 1987:33:2024-2027.
19. WAAGE A, ESPEVIK T, LAMVTK J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986;24:739-743.
20. SCUDERI P, LAM KS, RYAN KJ, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986;2:1364-1365.
21. THEOLOGIDES A. Pathogenesis of cachexia in cancer a review and a hypothesis. Cancer 1972;29:484-488.
22. BERENT SL, TORCZYNSKI RM, BOLLON AP. Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes. Nucleic Acids Res 1986;14:8997-9015.
23. LOWRY OH, ROSENBROUGH NJ, FARR AL, et al. Protein measurement with the Folin phenol reagent J Biol Chem 1951;193:265- 275.
24. RUFF MR, GIFFORD GE. Rabbit tumor necrosis factor mechanism of action. Infect Immun 1981:31:380-385.
25. SOCHER SH, RIEMEN MW, MARTINEZ D, et al. Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor. Proc Natl Acad Sci USA 1987;84:8829-8833.
26. 2b immunoglobulins from mouse serum using protein ASepharose. Immunochemistry 1978;15:429- 436.
27. NAKANO K, ABE S, SOHMURA Y. Recombinant human tumor necrosis factor. I. Cytotoxic activity in vitro. Int J Immunopharmacol 1986;8:347-355.
28. WATERHOUSE C. HOW tumors affect host metabolism. Ann NY Acad Sci 1974;230:86- 93.
29. ELLISON ML, NEVILLE AM. Neoplasia and ectopic hormone production. In: Raven RW, ed. Modem trends in oncology, vol 1. London: Butterworths, 1973:163-181.
30. MASUNO H, YAMASAKI N, OKUDA H. Purification and characterization of a lipolytic factor (toxohormone-L) from cell-free fluid of ascites sarcoma 180. Cancer Res 1981;41:284-288.
31. PEKALA PH, KAWAKAMI M, ANGUS CW, et al. Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 1983;80:2743-2747.